SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-000244
Filing Date
2024-01-02
Accepted
2024-01-02 08:04:28
Documents
12
Period of Report
2023-12-28
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d231255d8k.htm   iXBRL 8-K 24494
  Complete submission text file 0001193125-24-000244.txt   146327

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA urgn-20231228.xsd EX-101.SCH 2846
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20231228_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20231228_pre.xml EX-101.PRE 11258
6 EXTRACTED XBRL INSTANCE DOCUMENT d231255d8k_htm.xml XML 3357
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 24500297
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)